Genpharmasec Limited announced its unaudited financial results for the quarter ended December 31, 2025, demonstrating significant growth in standalone operations while navigating integration challenges in its consolidated business. The Board of Directors approved these results at their meeting held on February 09, 2026, pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Meeting and Regulatory Compliance

The company formally communicated the outcome of its Board meeting to BSE Limited, confirming that the meeting commenced at 04:00 p.m. and concluded at 04:40 p.m. on February 09, 2026. The Board considered and approved the unaudited standalone and consolidated financial results along with the limited review report of the auditor for the quarter ended December 31, 2025.

Standalone Financial Performance

The company delivered exceptional standalone revenue growth, with revenue from operations reaching Rs. 3,600.83 lakhs in Q3FY26, representing a substantial increase of 332.00% compared to Rs. 833.56 lakhs in Q3FY25. For the nine-month period ended December 31, 2025, standalone revenue grew to Rs. 7,968.51 lakhs from Rs. 1,940.80 lakhs in the corresponding period of the previous year.

Despite strong revenue performance, standalone profit before tax declined to Rs. 48.77 lakhs from Rs. 171.44 lakhs in the previous year quarter. Net profit for the quarter stood at Rs. 75.64 lakhs compared to Rs. 110.50 lakhs in Q3FY25, primarily due to higher cost of materials consumed which increased to Rs. 3,384.96 lakhs from Rs. 822.19 lakhs.

Consolidated Operations Show Integration Challenges

Consolidated financial results reflected the impact of recent acquisitions and business integration efforts. Consolidated revenue from operations grew to Rs. 3,982.81 lakhs in Q3FY26 from Rs. 848.41 lakhs in Q3FY25. However, the company reported a consolidated loss before tax of Rs. 133.22 lakhs compared to a profit of Rs. 126.90 lakhs in the corresponding quarter of the previous year.

Segment-wise Performance Analysis

The company operates across three primary segments: Pharmaceuticals, Laboratory Testing, and Manufacturing & Processing. The pharmaceuticals segment generated revenue of Rs. 3,681.83 lakhs in Q3FY26, while the newly added Manufacturing & Processing segment contributed Rs. 278.79 lakhs. However, this segment reported a loss of Rs. 123.95 lakhs, indicating integration challenges following the Derren Healthcare acquisition.

Key Corporate Developments

During the year ended March 31, 2024, the company entered into agreements with Derren Healthcare Private Limited for acquiring a 70% stake. The acquisition was completed on July 25, 2025, making Derren Healthcare a subsidiary. This acquisition has contributed to the Manufacturing & Processing segment but is currently showing operational losses as integration efforts continue.

The company also implemented significant accounting policy changes, reclassifying certain equity shares from inventories to financial investments. These instruments are now measured at fair value through other comprehensive income (FVOCI), resulting in a decrease in inventories of Rs. 89.32 lakhs with a net impact on total comprehensive income of Rs. (19.67) lakhs.

Earnings Per Share and Capital Structure

Standalone basic and diluted earnings per share stood at Rs. 0.01 for Q3FY26 compared to Rs. 0.02 in Q3FY25. On a consolidated basis, the company reported a loss per share of Rs. (0.02) for the quarter. The paid-up equity share capital remained stable at Rs. 5,537.20 lakhs with a face value of Re. 1 per share.

Regulatory and Compliance Updates

The company noted the implementation of New Labour Codes effective from November 21, 2025, which consolidated 29 existing labour legislations into four codes. Management's assessment, including actuarial valuation, indicated no material incremental impact on gratuity obligations, and no adjustments were made to the financial results for the quarter.

Genpharmasec Limited , a prominent player in the pharmaceutical and laboratory testing sectors, has announced its unaudited financial results for the first quarter, ending June 30. The company has demonstrated robust growth across key financial metrics on both standalone and consolidated bases.

Standalone Performance

On a standalone basis, Genpharmasec Limited reported impressive growth in its revenue from operations. The company's revenue surged to Rs 1,211.32 lakh, marking a significant increase of 128% compared to Rs 530.29 lakh in the same quarter of the previous year.

The company's profitability also saw substantial improvement. Profit for the period rose to Rs 155.92 lakh, up from Rs 58.87 lakh, representing a remarkable growth of 165%.

Consolidated Results

Genpharmasec's consolidated performance mirrored its standalone success. The consolidated revenue from operations reached Rs 1,204.32 lakh, compared to Rs 519.50 lakh in the previous year's quarter, showcasing a strong growth of 132%.

Consolidated profit for the period stood at Rs 121.52 lakh, a significant increase from Rs 28.68 lakh, reflecting a growth of 324%.

Segment-wise Performance

The company operates primarily in two segments: pharmaceuticals and laboratory testing. The pharmaceutical segment continued to be the major revenue driver, contributing Rs 1,167.09 lakh to the consolidated revenue. The laboratory testing segment, operated through its subsidiary Clinigenome India Private Limited, generated revenue of Rs 37.24 lakh.

Financial Highlights

Other Key Developments

The company's Board of Directors, in a meeting held on August 7, reviewed and approved these unaudited financial results. The meeting commenced at 2:00 p.m. and concluded at 2:50 p.m.

Genpharmasec Limited also reported that there has been no deviation in the use of proceeds from its rights issue, as confirmed in its statement to the BSE Limited.

Conclusion

Genpharmasec Limited's quarterly results demonstrate the company's ability to achieve significant growth in both revenue and profitability. The substantial year-over-year increases in key financial metrics reflect the company's strong market position and operational efficiency in the pharmaceutical and laboratory testing sectors.